---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-030579"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2026-01-30T23:59:59+00:00"
generated_at: "2026-05-16T06:02:09.570882+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology prices ~$150M equity offering at $1.57/share; includes pre-funded warrants

## Summary
- Gross proceeds expected ~$150M from sale of 76,979,112 common shares at $1.57 and pre-funded warrants for 18,574,120 shares at $1.569.
- Offering led by new investors RA Capital Management and TCGX, with participation from existing investors.
- Net proceeds to fund evorpacept and ALX2004 clinical trials, working capital.
- Expected close on or about Feb 2, 2026, subject to customary conditions.

## SEC filing metadata
- accession: 0001193125-26-030579
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2026-01-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000119312526030579/0001193125-26-030579-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000119312526030579/d12882d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-030579
- JSON: https://secwatch.observer/filing/0001193125-26-030579.json
- Plain text: https://secwatch.observer/filing/0001193125-26-030579.txt

## Key facts
- Material Agreements
  ALX ONCOLOGY HOLDINGS INC entered into Underwriting Agreement with Piper Sandler & Co., UBS Securities LLC and Wells Fargo Securities, LLC as representatives of the several underwriters valued at approximately $150 million (effective 2026-01-30).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Piper Sandler & Co., UBS Securities LLC and Wells Fargo Securities, LLC as representatives of the several underwriters
  - Value: approximately $150 million
  - Effective: 2026-01-30
  source text: On January 30, 2026, ALX Oncology Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co., UBS Securities LLC and Wells Fargo Securities, LLC as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 76,979,112 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at an offering price of $1.57 per share and pre-funded warrants (the “Pre-Funded Warrants”) to purchase 18,574,120 shares of Common Stock at an offering price of $1.569 per Pre-Funded Warrant.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000119312526030579/0001193125-26-030579-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.